Brainstorm Cell Therapeutics Company Profile (NASDAQ:BCLI)

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BCLI
  • CUSIP:
Key Metrics:
  • Previous Close: $3.94
  • 50 Day Moving Average: $2.94
  • 200 Day Moving Average: $2.51
  • 52-Week Range: $2.06 - $4.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.96
  • P/E Growth: 0.00
  • Market Cap: $82.60M
  • Outstanding Shares: 18,687,000
  • Beta: 1.81
Profitability:
  • Return on Equity: -46.80%
  • Return on Assets: -41.19%
Debt:
  • Current Ratio: 9.56%
  • Quick Ratio: 9.56%
Additional Links:
Companies Related to Brainstorm Cell Therapeutics:

Analyst Ratings

Consensus Ratings for Brainstorm Cell Therapeutics (NASDAQ:BCLI) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (33.04% upside)

Analysts' Ratings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Show:
DateFirmActionRatingPrice TargetDetails
12/20/2016Maxim GroupBoost Price TargetBuy$5.00 -> $6.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/15/2016Q3 2016($0.11)($0.09)ViewN/AView Earnings Details
8/11/2016Q2($0.18)($0.05)ViewN/AView Earnings Details
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details
11/13/2014Q3 14($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Current Year EPS Consensus Estimate: $-0.30 EPS
Next Year EPS Consensus Estimate: $-0.91 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.10)($0.10)($0.10)
Q3 20161($0.10)($0.10)($0.10)
Q4 20161($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Insider Ownership Percentage: 23.70%
Institutional Ownership Percentage: 9.22%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.00View SEC Filing  
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.20View SEC Filing  
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.40View SEC Filing  
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00View SEC Filing  
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00View SEC Filing  
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.00View SEC Filing  
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
DateHeadline
News IconBrainstorm Cell Therapeutics Inc. NASDAQ:BCLI Placed on Most Volatile List - Aiken Advocate (NASDAQ:BCLI)
aikenadvocate.com - February 22 at 3:53 PM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Signs Agreement with CCRM to Support Market Authorization Request for NurOwn in Canada (NASDAQ:BCLI)
www.streetinsider.com - February 21 at 4:04 PM
investopedia.com logoBrainStorm Seeks ALS Drug Nod In Canada (BCLI) (NASDAQ:BCLI)
www.investopedia.com - February 21 at 4:04 PM
us.rd.yahoo.com logoBrainStorm seeks early approval for stem cell treatment in Canada (NASDAQ:BCLI)
us.rd.yahoo.com - February 21 at 4:04 PM
us.rd.yahoo.com logoBrainStorm Seeking Approval To Distribute NurOwn® in Canada (NASDAQ:BCLI)
us.rd.yahoo.com - February 21 at 4:04 PM
us.rd.yahoo.com logo7:06 am Brainstorm Cell Therapeutics signs an agreement w/ CCRM to support the market authorization request for NurOwn (NASDAQ:BCLI)
us.rd.yahoo.com - February 21 at 4:04 PM
News IconBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Pushing Higher Before Market Open - Aiken Advocate (NASDAQ:BCLI)
aikenadvocate.com - February 21 at 11:45 AM
streetinsider.com logoBrainstorm Cell Therapeutics (BCLI) Signs Agreement with CCRM to Support Market Authorization Request for ... - StreetInsider.com (NASDAQ:BCLI)
www.streetinsider.com - February 21 at 11:45 AM
investopedia.com logoBrainStorm Seeks ALS Drug Approval In Canada (NASDAQ:BCLI)
www.investopedia.com - February 21 at 11:45 AM
finance.yahoo.com logoCity of Hope to Manufacture NurOwn® for Brainstorm's Phase 3 ALS Clinical Trial (NASDAQ:BCLI)
finance.yahoo.com - February 16 at 8:46 AM
prnewswire.com logoBrainStorm CEO to Present at the BIO CEO & Investor Conference - PR Newswire (press release) (NASDAQ:BCLI)
www.prnewswire.com - February 7 at 1:55 AM
finance.yahoo.com logoBrainStorm CEO to Present at the BIO CEO & Investor Conference (NASDAQ:BCLI)
finance.yahoo.com - February 6 at 3:51 PM
News IconBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Daily Sentiment Score At 0.435 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - February 5 at 3:50 PM
News IconIncrease in Volatility Draws Attention to Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Nelson Research (NASDAQ:BCLI)
nelsonobserver.com - February 2 at 9:00 PM
News IconOn the Hunt For the Next Wonder Stock: Penny Stock Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Nelson Research (NASDAQ:BCLI)
nelsonobserver.com - February 1 at 4:02 PM
News IconStock Carving Out Mid-Session Gains For Traders: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Wall Street Beacon (NASDAQ:BCLI)
wsbeacon.com - February 1 at 4:02 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Nelson Research (NASDAQ:BCLI)
nelsonobserver.com - February 1 at 2:06 AM
News IconSmall Cap Concentration on Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - February 1 at 2:06 AM
sbwire.com logoAll Penny Stocks.com News: Brainstorm Cell Therapeutics Starts Cryopreserved Trial (NASDAQ:BCLI)
www.sbwire.com - January 30 at 9:56 PM
News IconIs This Stock Capable of a Bull Run: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Nelson Research (NASDAQ:BCLI)
nelsonobserver.com - January 30 at 4:55 PM
finance.yahoo.com logoBrainStorm Announces Validation of NurOwn® Cryopreservation Process (NASDAQ:BCLI)
finance.yahoo.com - January 30 at 1:52 AM
News IconBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Daily Sentiment Score At 0.218 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - January 29 at 3:51 PM
News IconAre Investors Shying Away from Brainstorm Cell Therapeutics Inc ... - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 26 at 4:18 PM
News IconCan This Stock Make a Ripple in the Market: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 25 at 9:05 PM
4-traders.com logoBrainstorm Cell Therapeutics : The Life Sciences Report Asks If It Is Time to Go Long on BrainStorm Cell Therapeutics (NASDAQ:BCLI)
www.4-traders.com - January 24 at 4:21 PM
News IconBoom or Bust? Is there any value in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 24 at 2:20 AM
News IconAre There Catalysts to Propel This Stock Forward: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 23 at 9:19 PM
finance.yahoo.com logoThe Life Sciences Report Asks If It Is Time to Go Long on BrainStorm Cell Therapeutics (NASDAQ:BCLI)
finance.yahoo.com - January 23 at 4:12 PM
News IconBrainstorm Cell Therapeutics (BCLI) – Brokers Update Their Views - NewsDen (NASDAQ:BCLI)
newsden.net - January 21 at 3:47 PM
News IconBrainstorm Cell Therapeutics (BCLI) Analyst Coverage - NewsDen (NASDAQ:BCLI)
newsden.net - January 19 at 10:01 PM
News IconBrainstorm Cell Therapeutics (BCLI) Under Analyst Spotlight - UK ... - UK Market News (NASDAQ:BCLI)
www.ukmarketnews.co.uk - January 19 at 5:00 PM
News IconShort Interest Worth Mentioning Today: Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Just Reported ... - Baxley Report (NASDAQ:BCLI)
baxleyreport.com - January 19 at 5:00 PM
News IconIs This The Right Stock For Heady Investors: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 19 at 5:00 PM
News IconPlacing This Stock in the Hotbed: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 17 at 9:34 PM
News IconTime to Go Long on BrainStorm Cell Therapeutics? (NASDAQ:BCLI)
jutiagroup.com - January 17 at 4:33 PM
finance.yahoo.com logoBrainStorm CEO to Present at the Phacilitate Cell & Gene Therapy World Conference 2017 in Miami (NASDAQ:BCLI)
finance.yahoo.com - January 17 at 9:38 AM
News IconIs There Any Upside to This Stock Under $5: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 16 at 8:53 PM
News IconBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Daily Sentiment ... - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - January 15 at 8:47 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Wall Street Beacon (NASDAQ:BCLI)
wsbeacon.com - January 14 at 3:49 PM
News IconBrainStorm Cell Therapeutics Inc BCLI Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BCLI)
www.bioportfolio.com - January 14 at 3:22 AM
News IconBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Quarterly EPS Set At $-0.1 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - January 13 at 4:29 PM
News IconDaily Sentiment Score Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) At 0 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - January 8 at 8:49 PM
News IconQuarterly EPS Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) At $-0.1 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - January 6 at 4:02 PM
News IconAstute Investors Are Taking a Look at Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 5 at 4:11 PM
News IconTop Stock With Upside & Growth Potential: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - January 3 at 8:04 AM
News IconDaily Sentiment Score Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) At -0.115 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - January 2 at 3:45 PM
News IconCurious Investors Should Take a Look at This Small Cap Stock: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Prospect Journal (NASDAQ:BCLI)
prospectjournal.com - December 28 at 3:49 PM
News IconBearish Target Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) At $12 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - December 28 at 3:49 PM
News IconBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Daily Sentiment Score At 0.223 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - December 26 at 3:43 PM
News IconBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Quarterly EPS Seen At $-0.1 - Stock Observer (NASDAQ:BCLI)
www.thestockobserver.com - December 24 at 3:47 PM

Social

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Where is Brainstorm Cell Therapeutics' stock going? Where will Brainstorm Cell Therapeutics' stock price be in 2017?

1 equities research analysts have issued 12-month target prices for Brainstorm Cell Therapeutics' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Brainstorm Cell Therapeutics' stock price to reach $6.00 in the next twelve months.

When will Brainstorm Cell Therapeutics announce their earnings?

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns Brainstorm Cell Therapeutics stock?

Brainstorm Cell Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (2.14%) and Psagot Investment House Ltd. (0.21%). Company insiders that own Brainstorm Cell Therapeutics stock include International Holdings Ltd Acc, Malcolm S Taub, Robert G L Shorr and Yoram Bibring.

Who bought Brainstorm Cell Therapeutics stock? Who is buying Brainstorm Cell Therapeutics stock?

Brainstorm Cell Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include International Holdings Ltd Acc and Yoram Bibring.

How do I buy Brainstorm Cell Therapeutics stock?

Shares of Brainstorm Cell Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Brainstorm Cell Therapeutics stock cost?

One share of Brainstorm Cell Therapeutics stock can currently be purchased for approximately $4.51.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Earnings History Chart

Earnings by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Dividend History Chart

Dividend Payments by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Last Updated on 2/22/2017 by MarketBeat.com Staff